In this webinar, we delve into the synthetic methodologies, pharmacology and overall drug discovery considerations associated with the development of covalent inhibitors in drug discovery. The most important points are highlighted using flagship case studies containing valuable industry insight.
Covalent inhibition has seen a rebirth in the last decade. Prosecuting covalent inhibitor programmes requires a complete rethinking of the drug discovery process. This webinar, in association with Concept Life Sciences, aims to provide the foundations and emerging paradigms in covalent drug discovery.
The content has been designed for scientists with a general interest in drug discovery. No prior knowledge is required, and this webinar also acts as a tutorial.
By watching this webinar you will:
- Learn about the fundamental aspects of developing covalent inhibitors in drug discovery
- Discover more about the new warheads under development
- Understand the in-vitro and in-vivo considerations associated with this therapeutic strategy
- Develop a feel for the emerging paradigms in this field
Speaker: Matilda Bingham (Tilly), VP of science, Concept Life Sciences
Speaker: Jamie Stokes, principal scientist, Concept Life Sciences
Speaker: Daniel Glynn, principal scientist, Concept Life Sciences
Speaker: Caroline Rigby, senior chemist, Concept Life Sciences
Moderator: Benjamin Valsler, digital editor, Chemistry World
Concept Life Sciences offers a comprehensive range of discovery and development services and analytical solutions across the pharmaceutical, biotechnology, agrochemical and food sectors.
We’ve been delivering projects globally for over 25 years and our team of 250+ scientists has extensive experience in multiple therapy areas with specialist expertise in immunology, oncology and neuroscience.
We offer a comprehensive range of discovery and development services and analytical solutions across the pharmaceutical, biotechnology, agrochemical and food sectors. Our services are built on expert knowledge, collaboration, flexibility and extensive in-house resources.